Avalia - Model AVA2300 - Influenza Prevention Vaccine
Influenza severely affects over 3 million people annually and results in up to 650,000 deaths annually from the associated respiratory diseases caused by seasonal influenza. Due to frequent mutations of the influenza virus, current strain-specific influenza vaccines are not designed to offer protection against mutated flu strains that are not contained in the latest seasonal influenza vaccine.
Details
This means seasonal influenza vaccines are reformulated annually to improve protection amongst the community. Long-term protection is inadequate and the holy grail is the design of a universal influenza vaccine that offers cross-strain protection and reduces vaccination frequency.
Avalia’s vaccines have shown to generate powerful T cell immunity in preclinical models, offering the potential of universal protection and the ability to combine with existing vaccines.
Customer reviews
No reviews were found for Avalia - Model AVA2300 - Influenza Prevention Vaccine. Be the first to review!